Hovione and Firstgene Life Sciences have entered a strategic collaboration to advance Hovione’s virus-like particle drug ...

DelveInsight's Hepatocellular Carcinoma pipeline report depicts a robust space with 90+ active players working to develop 95+ pipeline therapies for Hepatocellular Carcinoma treatment.

The researchers also show that the antibody reshapes the immune landscape of tumors isolated from HCC patients, suggesting it ...

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory diseases (“Can-Fite” or ...

Presented new amezalpat mechanism-of-action data reinforcing its potential as a novel cancer treatment at the 2025 AACR ...

The US Food and Drug Administration (FDA ... for adults with unresectable or metastatic hepatocellular carcinoma (HCC). Median overall survival, the primary outcome measure, was 23.7 months ...

Replimune Group, Inc.'s RP1 + OPDIVO for advanced melanoma gains FDA Priority Review. PDUFA date: July 22, 2025. Read more on REPL stock prospects.

A new study has identified a specific mode of fat uptake by immune cells within tumors that serves as a metabolic checkpoint against anti-cancer immune responses.